Events | Arcalyst

Past Webinars

Introducing ARCALYST (rilonacept) - The first and only FDA-approved therapy that treats recurrent pericarditis and reduces the risk of future flares

Speakers:

Dr. Martin LeWinter, Cardiologist at University of Vermont Medical Center
Dana Martin, Senior Vice President of Global Medical Affairs and Patient Advocacy at Kiniksa Pharmaceuticals
April Scott, Senior Director of Patient Services at Kiniksa Pharmaceuticals

About Webinar:

Join Dr. Martin LeWinter, Cardiologist at University of Vermont Medical Center, to learn about a new treatment option for recurrent pericarditis.

April Scott, Senior Director of Patient Services at Kiniksa Pharmaceuticals will introduce Kiniksa OneConnect, a patient support program designed to provide you with personalized support through your treatment journey.

During this educational webinar you will learn about:

Recurrent pericarditis
Treatment with ARCALYST
Support services offered by Kiniksa OneConnect

Important Safety Information

ARCALYST may affect your immune system and can lower the ability of your immune system to fight infections. Serious infections, including life-threatening infections and death, have happened in patients taking ARCALYST. If you have any signs of an infection, call your doctor right away. Treatment with ARCALYST should be stopped if you get a serious infection. You should not begin treatment with ARCALYST if you have an infection or have infections that keep coming back (chronic infection).
While taking ARCALYST, do not take other medicines that block interleukin-1, such as Kineret® (anakinra), or medicines that block tumor necrosis factor, such as Enbrel® (etanercept), Humira® (adalimumab), or Remicade® (infliximab), as this may increase your risk of getting a serious infection.
Talk with your doctor about your vaccine history. Ask your doctor whether you should receive any vaccines before you begin treatment with ARCALYST.
Medicines that affect the immune system may increase the risk of getting cancer.
Stop taking ARCALYST and call your doctor or get emergency care right away if you have any symptoms of an allergic reaction.
Your doctor will do blood tests to check for changes in your blood cholesterol and triglycerides.
Common side effects include injection-site reactions (which may include pain, redness, swelling, itching, bruising, lumps, inflammation, skin rash, blisters, warmth, and bleeding at the injection site), upper respiratory tract infections, joint and muscle aches, rash, ear infection, sore throat, and runny nose.

For more information about ARCALYST, talk to your doctor and see the Product Information.

INDICATION

ARCALYST® (rilonacept) is an interleukin-1 blocker indicated for:

Treatment of Recurrent Pericarditis (RP) and reduction in risk of recurrence in adults and pediatric patients 12 years and older.
Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS), and Muckle-Wells Syndrome (MWS) in adults and children 12 years and older.
Maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing 10 kg or more.

Go Back Continue